SNDX - BofA starts Syndax at buy cites first mover advantage for leukemia drug
2023-10-25 16:02:55 ET
More on Syndax Pharmaceuticals
- Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023
- Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results
- Syndax Pharmaceuticals, Inc. (SNDX) Q2 2023 Earnings Call Transcript
- Syndax initiated Buy at Goldman Sachs citing sales ops next year
- Biggest stock movers today: Arch Resources, Coinbase Global and more
For further details see:
BofA starts Syndax at buy, cites "first mover advantage" for leukemia drug